ArticleJournal of bioenergetics and biomembranes2026
Application of glutamine metabolism-related gene signatures in the non-invasive diagnosis of coronary artery disease: integrating bulk and single-cell transcriptomics.
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is a common cardiovascular disorder strongly associated with glutamine metabolism. This study seeks to identify novel glutamine metabolism-related gene markers in CAD. Based on GEO datasets and glutamine metabolism-related genes, hub genes were pinpointed through WGCNA combined with LASSO, SVM-RFE, and random forest algorithms. Immune cell infiltration was estimated with the CIBERSORT algorithm. To confirm the expression and roles of hub genes, ox-LDL-stimulated HUVECs were analyzed in culture. MYBPC3 and TRIM47 emerged as candidate diagnostic signatures for CAD. Associations between MYBPC3/TRIM47 and immune cell infiltration were revealed. Upregulation of MYBPC3 and TRIM47 in CAD was confirmed in both GSE113079 and ox-LDL-treated HUVECs. Knockdown of TRIM47 or MYBPC3 promoted ox-LDL-induced proliferation of HUVECs, alleviated cellular apoptosis, and suppressed the expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) as well as M1 macrophage polarization. MYBPC3 and TRIM47 may serve as candidate diagnostic signatures for CAD.
Indexed as
Identifiers
42530694What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.